I'm a bit paranoid/concerned about this issue. Most (all?) of the psychedelics are agonists of the 5ht2b receptor. I don't imagine tripping once a month could possibly make this a risk, but it's probably the one thing that holds me back from microdosing all the time.
This is a document with the affinity of many psychedelics for receptors 5h-t2b:
5ht2b: 4.00 DOB, 4.00 MDA, 4.00 Aleph-2, 4.00 2C-B-fly, 4.00 2C-B, 4.00 TMA, 4.00 psilocin, 4.00 TMA-2, 4.00 2C-E, 4.00 2C-T-2, 4.00 4C-T-2, 4.00 MEM, 4.00 DOM, 3.97 mescaline, 3.93 6-F-DMT, 3.91 5-MeO-DIPT, 3.91 DMT, 3.88 DPT, 3.70 DOET, 3.64 MDMA, 3.48 DIPT, 3.32 5-MeO-MIPT, 3.13 DOI, 3.11 LSD, 3.01 lisuride, 2.72 cis-2a, 2.17 SS-2c, 1.81 RR-2b, 0.69 5-MeO-DMT; 0.00 salvinorin A;
ND: 5-MeO-TMT, ibogaine, EMDT, morphine, THC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009019
With lysergamides, another risk (microdosing) to consider would be this one:
Medicines containing substances known as ergot derivatives can have serious side effects, called fibrosis and ergotism. As a result, they should no longer be used in the EU to treat a number of conditions involving blood circulation problems (that usually affect elderly patients) or problems with memory and sensation, or to prevent migraine headaches, as the risks outweigh the benefits.
This is based on a review of data showing an increased risk of fibrosis (formation of excess connective tissue that can damage organs and body structures) with these medicines.
Ergot derivatives are recognised as being capable of inducing fibrosis, in particular heart-valve fibrosis, through serotoninergic-receptor activation, which is extensively described in the literature. The varying affinity for serotoninergic receptors of the different ergot derivatives, and the therapeutic doses used, may explain the differences observed in reporting frequencies for the fibrotic reactions.
http://www.ema.europa.eu/ema/index....ews_detail_001832.jsp&mid=WC0b01ac058004d5c1b
Probably from War on Drugs propaganda attacking the Shulgin's reputation. Alexander Shuglin spent decades developing psychedelic medicines.
Hence, the governments attacked the reputation of the people promoting psychedelics in an attempt at discrediting the work they do..
Shulgin worked (indirectly?) to the government:
Martin A. Lee said:
STP (aka DOM) was developed in 1964 by an experimental chimist working for the Dow Chemical Company, which provided samples of the drug to Edgewood Arsenal, headquarters of the US Army Chemical Corps...In early 1967, for some inexplicable reason, the formula for STP was released to the scientific communauty at large...
https://books.google.fr/books?id=_o...#v=onepage&q=STP dow chemical company&f=false